Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 12, 983 (1 September 2006) | doi:10.1038/nm0906-983a;
Drug companies accused of stalling tailored therapies
Abstract
Therapies tailored for people's distinct genetic makeup have for years been touted as the next big thing in drug development. But if those drugs have yet to materialize, it may be because drug companies don't want them to.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).